CHARALAMPOS THEOCHAROPOULOS

Dr. CHARALAMPOS THEOCHAROPOULOS


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
DZDimitrios C Ziogas
Dimitrios C Ziogas
CTCHARALAMPOS THEOCHAROPOULOS
CHARALAMPOS THEOCHAROPOULOS
TKTilemachos Koutouratsas
Tilemachos Koutouratsas
JHJohn Haanen
John Haanen
HGHelen Gogas
Helen Gogas

11 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DZDimitrios C Ziogas
Dimitrios C Ziogas
CTCHARALAMPOS THEOCHAROPOULOS
CHARALAMPOS THEOCHAROPOULOS
PLPanagiotis-Petros Lialios
Panagiotis-Petros Lialios
DFDimitra Foteinou
Dimitra Foteinou
IKIoannis-Alexios Koumprentziotis
Ioannis-Alexios Koumprentziotis
HGHelen Gogas
Helen Gogas
More than ten years after the approval of ipilimumab, immune checkpoint inhibitors (ICIs) against PD-1 and CTLA-4 have been established as the most effective treatment for locally advanced or metastatic melanoma, achieving durable responses either as monotherapies or in combinatorial regimens. However, a considerable proportion of patients do not respond or experience early relapse, due to multiple parameters that contribute to melanoma resistance. The expression of other immune checkpoints beyond the PD-1 and CTLA-4 molecules remains a major mechanism of immune evasion. The recent approval of anti-LAG-3 ICI, relatlimab, in combination with nivolumab for metastatic disease, has capitalized on the extensive research in the field and has highlighted the potential for further improvement of melanoma prognosis by synergistically blocking additional immune targets with new ICI-doublets, antibody–drug conjugates, or other novel modalities. Herein, we provide a comprehensive overview of presently published immune checkpoint molecules, including LAG-3, TIGIT, TIM-3, VISTA, IDO1/IDO2/TDO, CD27/CD70, CD39/73, HVEM/BTLA/CD160 and B7-H3. Beginning from their immunomodulatory properties as co-inhibitory or co-stimulatory receptors, we present all therapeutic modalities targeting these molecules that have been tested in melanoma treatment either in preclinical or clinical settings. Better understanding of the checkpoint-mediated crosstalk between melanoma and immune effector cells is essential for generating more effective strategies with augmented immune response.

29 September 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
CTCHARALAMPOS THEOCHAROPOULOS
CHARALAMPOS THEOCHAROPOULOS
PLPanagiotis-Petros Lialios
Panagiotis-Petros Lialios
MSMichael Samarkos
Michael Samarkos
HGHelen Gogas
Helen Gogas
DZDimitrios C Ziogas
Dimitrios C Ziogas
In the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of attached payloads. So far, ten ADCs have been approved by FDA for oncological indications and many others are currently being tested in clinical and preclinical level. This paper summarizes the essential components of ADCs, from their functional principles and structure up to their limitations and resistance mechanisms, focusing on all latest bioengineering breakthroughs such as bispecific mAbs, dual-drug platforms as well as novel linkers and conjugation chemistries. In continuation of our recent review on anticancer implication of ADC’s technology, further insights regarding their potential usage outside of the oncological spectrum are also presented. Better understanding of immunoconjugates could maximize their efficacy and optimize their safety, extending their use in everyday clinical practice.

30 January 2025 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
DZDimitrios C Ziogas
Dimitrios C Ziogas
CTCHARALAMPOS THEOCHAROPOULOS
CHARALAMPOS THEOCHAROPOULOS
KAKaterina Aravantinou
Katerina Aravantinou
ABAristeidis Boukouris
Aristeidis Boukouris
DSDimitra Theodore Stefanou
Dimitra Theodore Stefanou
HGHelen Gogas
Helen Gogas
The age-related decline in immunity appears to be associated not only with cancer development but also with differential responses to immune checkpoint inhibitors (ICIs). Despite their increasing utility across various malignancies and therapeutic settings, limited data -derived primarily from subgroup analyses of randomized controlled trials (RCTs), pooled meta-analyses, and retrospective studies- are available on the effects of aging on their efficacy and toxicity. Immunosenescence, characterized by the progressive decline of the function of the immune system, and inflammaging, a state of persistent low-grade sterile inflammation, may influence ICI outcomes. Additionally, the incidence, severity, and subtypes of immune-related adverse events (irAEs) may differ between older and younger individuals due to loss of immunotolerance. In the current review, starting from a a comprehensive discussion of the pathophysiology of immunosenescence, we proceed to critically review age-related retrospective and randomized evidence supporting FDA-approved ICIs. We highlight similarities or differences across age groups and the clinical benefit of ICIs in elderly versus younger cancer patients. The optimal integration of ICIs in geriatric oncology necessitates greater inclusion of this patient demographic in RCTs along with real-world data in order to acquire robust data which will guide evidence-based treatment decisions for this population.

5 January 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
IKIoannis-Alexios Koumprentziotis
Ioannis-Alexios Koumprentziotis
CTCHARALAMPOS THEOCHAROPOULOS
CHARALAMPOS THEOCHAROPOULOS
DFDimitra Foteinou
Dimitra Foteinou
EAErasmia Angeli
Erasmia Angeli
AAAmalia Anastasopoulou
Amalia Anastasopoulou
DZDimitrios C Ziogas
Dimitrios C Ziogas
Immune checkpoints (ICs) are molecules implicated in the fine-tuning of immune response via co-inhibitory or co-stimulatory signals, and serve to secure minimized host damage. Targeting ICs with various therapeutic modalities, including checkpoint inhibitors/monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and CAR-T cells has produced remarkable results, especially in immunogenic tumors, setting a paradigm shift in cancer therapeutics through the incorporation of these IC-targeted treatments. However, the large proportion of subjects who experience primary or secondary resistance to available IC-targeted options necessitates further advancements that render immunotherapy beneficial for a larger patient pool with longer duration of response. B7-H3 (B7 Homolog 3 Protein, CD276) is a member of the B7 family of IC proteins that exerts pleiotropic immunomodulatory effects both in physiologic and pathologic contexts. Mounting evidence has demonstrated an aberrant expression of B7-H3 in various solid malignancies, including tumors less sensitive to current immunotherapeutic options, and has associated its expression with advanced disease, worse patient survival and impaired response to IC-based regimens. Anti-B7-H3 agents, including novel mAbs, bispecific antibodies, ADCs, CAR-T cells, and radioimmunotherapy agents, have exhibited encouraging antitumor activity in preclinical models and have recently entered clinical testing for several cancer types. In the present review, we concisely present the functional implications of B7-H3 and discuss the latest evidence regarding its prognostic significance and therapeutic potential in solid malignancies, with emphasis on anti-B7-H3 modalities that are currently evaluated in clinical trial settings. Better understanding of B7-H3 intricate interactions in the tumor microenvironment will expand the oncological utility of anti-B7-H3 agents and further shape their role in cancer therapeutics.

26 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CTCHARALAMPOS THEOCHAROPOULOS
CHARALAMPOS THEOCHAROPOULOS
SDSpyridon Davakis
Spyridon Davakis
DZDimitrios C Ziogas
Dimitrios C Ziogas
ATAchilleas Theocharopoulos
Achilleas Theocharopoulos
DFDimitra Foteinou
Dimitra Foteinou
ACAlexandros Charalabopoulos
Alexandros Charalabopoulos
Esophageal cancer has a dismal prognosis and necessitates a multimodal and multidisciplinary approach from diagnosis to treatment. High-definition white-light endoscopy and histopathological confirmation remain the gold standard for the definitive diagnosis of premalignant and malignant lesions. Artificial intelligence using deep learning (DL) methods for image analysis constitutes a promising adjunct for the clinical endoscopist that could effectively decrease BE overdiagnosis and unnecessary surveillance, while also assisting in the timely detection of dysplastic BE and esophageal cancer. A plethora of studies published during the last five years have consistently reported highly accurate DL algorithms with comparable or superior performance compared to endoscopists. Recent efforts aim to expand DL utilization into further aspects of esophageal neoplasia management including histologic diagnosis, segmentation of gross tumor volume, pretreatment prediction and post-treatment evaluation of patient response to systemic therapy and operative guidance during minimally invasive esophagectomy. Our manuscript serves as an introduction to the growing literature of DL applications for image analysis in the management of esophageal neoplasia, concisely presenting all currently published studies. We also aim to guide the clinician across basic functional principles, evaluation metrics and limitations of DL for image recognition to facilitate the comprehension and critical evaluation of the presented studies.